Bicycle Therapeutics secures 400-tonne reprocessed uranium supply in 15-year NDA deal
Bicycle Therapeutics (NASDAQ:BCYC), developer of a novel class of bicyclic peptide-based medicines, has secured a 15-year contract with the UK Nuclear Decommissioning Authority granting access to up to 400 tonnes of reprocessed uranium (RepU)—a resource the company says will underpin long-term production of lead-212 (212Pb) for its emerging cancer radioconjugate programs.










